Camrelizumab, previously known as SHR-1210, represents a significant advancement in tumor immunotherapy , functioning as a biologic that inhibits the programmed cell death 1 receptor. This control protein, expressed on lymphocytes , normally dampens antitumor immune responses, allowing malignant tissues to evade recognition by the body’s protecti